Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H5P4
UPID:
PDZD7_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H5P4; D5FJ77; Q8N321
Background:
PDZ domain-containing protein 7 plays a pivotal role in cochlear hair cell development, crucial for organizing the USH2 complex at stereocilia ankle links. It also negates ADGRV1-mediated inhibition of adenylate cyclase activity, highlighting its multifunctionality in cellular processes.
Therapeutic significance:
Linked to Deafness, autosomal recessive, 57, and Usher syndrome types 2A and 2C, understanding PDZ domain-containing protein 7's role could unveil new therapeutic avenues for these sensorineural conditions.